News Posts List
Take The 2015 Kidney Cancer Trivia Challenge!
03/01/2015
Use the hashtag #kidneycancer and @kidneycancer when you Tweet during March, Kidney Cancer Awareness Month. Help increase awareness and the need for a cure!
Body Mass Index Predicts Survival
03/01/2015
Body mass index (BMI) predicts survival and overall response (ORR) rates in patients with metastatic clear cell renal cell carcinoma, according to authors of an external validation data analysis (Abstract 405) presented during the 2015 Genitourinary Cancers Symposium.
March is Kidney Cancer Awareness Month
03/01/2015
Since its founding in 1990 by the late Eugene P. Schonfeld, Ph.D., KCA has developed scores of highly effective relationships with organizations and institutions around the world.
Combination Therapy with Sunitinib and Gemcitabine in Rapidly Progressive mRCC
03/01/2015
Standard single-agent treatment options offer meager prospects for metastatic sarcomatoid renal cell carcinoma (RCC) and poor-risk RCC, both of which demonstrate aggressive tumor biology and rapid clinical disease progression. However, results of a single-arm, open-label, phase II trial suggest that combining select treatment options may deliver the necessary punch to keep these aggressive forms of RCC in check (Abstract 408).
ASCO GU Keynote: Future Clinical Trials in Renal Cell Cancer
03/01/2015
Daniel J. George, MD, of Duke Cancer Institute, gives an overview of what is on the horizon in renal cell cancer (RCC) research. Topics discussed include emerging clinical trials, how to move forward with predictive biomarkers, clinical outcomes for RCC trials, and unmet needs in advanced RCC that Dr. George describes as being “imminently attainable.”
ASCO GU: The Future of Treatment for Advanced RCC
02/27/2015
Despite that several VEGF, VEGF receptor (VEGFR), and mTOR inhibitors are approved for metastatic renal cell carcinoma (mRCC), the benefit patients receive from these classes of agents has reached a plateau.
Patient Participation Vital To Research
02/26/2015
Kidney Cancer Association educates patients about the value of clinical trials.
Sunitinib, sorafenib of no benefit in ECOG-ACRIN renal cell trial
02/24/2015
Research results highlighted today at the press conference of a major medical meeting report no benefit from the use of either Sutent® (sunitinib) or Nexavar® (sorafenib) among patients with locally advanced renal cell carcinoma at high risk of recurrence...
Posttraumatic stress and depressive symptoms in renal cell carcinoma
02/23/2015
he purpose of this study was to examine the prevalence of posttraumatic stress symptoms (PTSS) in patients with renal cell carcinoma (RCC), the associations and co–occurrence between PTSS, depressive, and other cancer–related symptoms...
Phase 2 clinical trial on volitinib in papillary renal cell carcinoma
02/21/2015
At the Thirteenth International Kidney Cancer Symposium, Dr Toni Choueiri (Dana-Farber Cancer Institute and Harvard Medical School, MA) discusses the new AstraZeneca-sponsored Phase 2 clinical trial on the c-Met inhibitor, volitinib, in patients with papillary renal cell carcinoma (pRCC).
News Feed